Tested Applications
| Positive WB detected in | MOLT-4 cells, human peripheral blood leukocyte |
| Positive IHC detected in | human tonsillitis tissue, human appendicitis tissue, human breast cancer tissue, human colon tissue, human colon cancer tissue, human lung cancer tissue, human lymphoma tissue, human pancreas cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | human tonsillitis tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:10000 |
| Immunohistochemistry (IHC) | IHC : 1:10000-1:40000 |
| Immunofluorescence (IF)-P | IF-P : 1:400-1:1600 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
66868-1-Ig targets CD8a in WB, IHC, IF-P, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, pig, bovine |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag11111 Product name: Recombinant human CD8A protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 23-183 aa of BC025715 Sequence: QFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGCYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI Predict reactive species |
| Full Name | CD8a molecule |
| Calculated Molecular Weight | 235 aa, 26 kDa |
| Observed Molecular Weight | 32 kDa |
| GenBank Accession Number | BC025715 |
| Gene Symbol | CD8A |
| Gene ID (NCBI) | 925 |
| ENSEMBL Gene ID | ENSG00000153563 |
| RRID | AB_2882205 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein G purification |
| UNIPROT ID | P01732 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CD8 is a transmembrane glycoprotein that is predominantly expressed on the surface of cytotoxic T cells, and can also be found on natural killer cells, cortical thymocytes, and dendritic cells. CD8 serves as a co-receptor for the T cell receptor (TCR). Both CD8 and TCR recognize antigens displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. CD8 plays a role in T cell development and activation of mature T cells. This antibody is raised against 23-183 aa of human CD8a, the alpha chain of CD8 molecule.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for CD8a antibody 66868-1-Ig | Download protocol |
| IHC protocol for CD8a antibody 66868-1-Ig | Download protocol |
| WB protocol for CD8a antibody 66868-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
CD8a Monoclonal antibody (66868-1-Ig) has 342 total citations. Papers appear in high-impact journals including Signal Transduct Target Ther, Cancer Cell, Mol Cancer, Cell Metab, Nat Commun, Nat Cancer, Nat Genet, Cancer Commun, Cell Mol Immunol, J Immunother Cancer, Oncogene, Front Immunol, and Adv Sci. The research spans cancer immunology and immunotherapy (immune checkpoint inhibition, PD-L1/PD-1 mechanisms, tumor microenvironment, CD8+ T-cell tumor infiltration and exhaustion, CAR-T therapy, ferroptosis/pyroptosis), along with pan-cancer and single-cell profiling studies across breast, lung, gastric, colorectal, liver, bladder, cervical, and renal cancers.
| Species | Application | Title |
|---|---|---|
Signal Transduct Target Ther Krüppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy | ||
Cancer Cell Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups | ||
Cancer Cell Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer | ||
Mol Cancer Integrated multi-omics identifies a CD54(+) iCAF-ITGAL(+) macrophage niche driving immunosuppression via CXCL8-PDL1 axis in cervical cancer. | ||
Mol Cancer ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma. | ||
Mol Cancer The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments |
Reviews
What customers say
Able is busy answering your previous question. Please try again later.
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
MALLIKARJUNA (Verified Customer) (11-26-2025) | GODD FOR IF
|





















































